Biomarkers for action
We unlock the promise of precision medicine by providing comprehensive information of how cells respond to DNA damage in preclinical and clinical samples, helping pharmaceutical companies develop better treatments and helping doctors match the right patient to the best treatment.
A Francis Crick Institute spinout
Our vision is simple yet profound: every cancer patient examined, diagnosed, and treated according to the real-time functional behaviour of their tumour—making personalised medicine not just a goal, but a measurable reality.
Our Expertise
Expert scientists in the DNA damage response (DDR) with the right academic, industry, and commercial experience to integrate our technology into your development and decision-making pipeline.
Anaid Benitez PhD
Miroslav Ivanov PhD
Marek Adamowicz PhD
Vilibald Eugén Farkas
Lara Kay
Leandre Tappenden
Advisory Board
Stephen C. West PhD
Senior Principal Group Leader
The Francis Crick Institute
Mike Karim
Michael Howell
Head of HTS
The Francis Crick Institute
Bold Technology, Real Impact.
Find out more about our technology below and help shape the next generation of functional readouts.